LancetQiao et al.Original Research

878 pubs · 57,510 cites · h-index 116
LancetQiao et al.Original Research
Birth Defects ResearchVilleneuve et al.Systematic Review
Expert elicitation identifies risk factors affecting birth outcomes, suggesting priority areas for research.
Minerva Obstetrics and GynecologyTorkel et al.Review
INTRODUCTION: Female fertility is influenced by a complex interplay of lifestyle factors. They may include weight, diet, supplementation, physical activity, sleep and substance use. Understanding these factors, in combination with a thorough understanding of strategies to support effective behavior change is essential to develop effective lifestyle interventions for women who wish to enhance their fertility. This review aimed to summarize the evidence on female fertility and lifestyle, and to discuss intervention considerations which may affect implementation of the evidence. EVIDENCE ACQUISITION: Electronic databases (PubMed, Google Scholar) were searched to identify relevant peer-reviewed studies and evidence-based guidelines. EVIDENCE SYNTHESIS: The following lifestyle factors are associated with improved female fertility: maintaining a healthy weight, following a healthy dietary pattern (e.g. Mediterranean diet) with appropriate supplementation, participating in regular physical activity, attaining 7-8.5 hours of high-quality nocturnal sleep and avoiding or limiting substance use (caffeine, alcohol and smoking). Considering the factors affecting lifestyle management in both consumers (e.g. emotional eating and financial barriers) and health professionals (e.g. time constraints and concerns about patient expectations of care) is essential to optimize success of lifestyle interventions to improve fertility. CONCLUSIONS: Lifestyle management has an important role in improving reproductive health and overall health for women who wish to conceive. A patient-centered approach which incorporates behavioral science, individual preferences, and healthcare delivery considerations is essential. There is a need for further research to inform optimal intervention components and behavior change strategies for this population.
Human ReproductionBalen et al.Guideline
Eco-Environment & HealthChen et al.In Vitro Study
Few large-scale studies have systematically examined the effects of maternal exposure to fine particulate matter (PM 2.5 ) on live birth in women undergoing in vitro fertilization (IVF). This study aimed to investigate the associations between ambient PM 2.5 and live birth in women treated with IVF, and determine critical periods, key failure events, and vulnerable populations affected by such exposure. We included 58,637 patients from six reproductive centers in China between 2016 and 2021. We defined six exposure windows and adopted logistic regression with random-effect models to investigate the associations between PM 2.5 exposure and live birth. We further categorized live birth failure as implantation failure, biochemical pregnancy loss, and miscarriage, to determine at which stage PM 2.5 exposure caused the live birth failure. Subgroup analyses were conducted by female age, ovarian response, embryo quality, and transplantation protocol. For each 10 μg/m 3 increase in PM 2.5 concentration during follicle growth phase, preantral-antral follicle phase, and antral-mature follicle phase, the odds ratios for live birth were 0.966 [95% confidence interval (CI): 0.938, 0.995], 0.967 (0.939, 0.996), and 0.978 (0.958, 0.998), respectively. PM 2.5 during these stages was significantly associated only with an increased likelihood of implantation failure, highlighting adverse impact of ambient PM 2.5 on early pregnancy outcome. In addition, we observed relatively stronger associations in women with poor ovarian response, compromised embryo quality, and those undergoing fresh or double embryo transfers. This large-scale population-based study demonstrated the detrimental effects of high PM 2.5 exposure for IVF women, shedding light on clinical and public health practices. • Maternal high PM 2.5 exposure in follicular growth stages were significantly associated with decreased live birth. • The PM 2.5 -associated live birth failures primarily arise in the early pregnancy stages. • Women with poor ovarian response, diminished embryo quality, undergoing fresh or double embryo transfers may be more sensitive to PM 2.5 exposure.
Journal of Bioethical InquiryWiersma et al.Review
Scoping review outlines commercialization effects on ART services, suggesting strategies for patient protection.
Human Reproduction UpdateTorkel et al.Meta-Analysis
Systematic review shows lifestyle interventions improve weight loss and may affect fertility outcomes in women, suggesting targeted approaches could enhance effectiveness.
EClinicalMedicineTeede et al.Original Research
Background: Polycystic ovary syndrome (PCOS) has diverse features. However, the name reflects only ovarian aspects, overlooking broader features. This study aimed to investigate international stakeholder perspectives on PCOS. Methods: We conducted international longitudinal anonymous online surveys and face-to-face workshops with individuals with PCOS and health professionals between 2015 and 2023, across six continents, seeking perspectives on clinical features of PCOS, the current name, the potential for renaming, the advantages and disadvantages of a name change, and possible alternative names. Findings: Results from 7708 survey respondents in 2015 and post publication of international guidelines in 2023, significantly improved recognition of the reproductive, cardiometabolic, hormonal, and psychological features of PCOS (p < 0·001). However, gaps remain, with ≥20% of patients and/or health professionals not recognising associations between PCOS and non-alcoholic fatty liver disease, pregnancy complications, cardiovascular risk factors, and endometrial cancer. Aligned to the breadth of PCOS, in the 2023 survey, a potential name change was explored with 85·6% of patients and 76·1% of health professionals agreeing that the name should be changed. Both groups agreed that a name change presents advantages with 59-90% agreeing with advantages and fewer than 27% agreeing with disadvantages. Terms such as 'endocrine' and 'metabolic' received the highest support in 2015 and 2023 for inclusion in a new name among both patients (78·5 and 86·2%) and health professionals (84·6 and 79·6%). Overall, 84% committed to a consensus-driven name change process on voting at a 2023 workshop. Interpretation: Widespread international engagement in 2015 showed major knowledge gaps on broad PCOS features, with follow-up in 2023 showing significant improvement after two international guidelines, widespread dissemination and advocacy group outreach. Stakeholders highlighted that the current name does not adequately reflect broad PCOS features and is confusing. They endorsed a name change, with perceived advantages outweighing potential disadvantages. This culminated in a commitment to a global consensus process to determine and implement a new name, alongside extensive education efforts, both of which are now underway.
Frontiers in EndocrinologyNguyen et al.Retrospective Study
Objective: To evaluate whether progesterone (P4) supplementation in patients with low serum progesterone levels after normal luteal phase support (LPS) improves pregnancy outcomes in women undergoing frozen embryo transfer (FET). Methods: A retrospective, single-center cohort study including 1301 vitrified-warmed frozen embryo transfer (FET) cycles conducted from May 2021 to July 2023 at Vinmec Times City International Hospital. A total of 696 FET cycles from individual patients were analyzed for pregnancy outcome. Patients with serum P4 level ≥ 10 ng/ml (Normal P4, n=359) continued to receive standard LPS, while those with P4 levels < 10 ng/ml (Rescue P4, n=337) received 50 mg intramuscular P4 injection daily in addition to the standard LPS for 7-10 days. Results: Daily intramuscular P4 effectively restored serum P4 levels to that of the Normal P4 group and resulted in pregnancy outcome comparable to that of patients with P4 levels ≥10 ng/ml. Notably, the efficacy of this protocol was consistent even in very low serum P4 concentrations (< 4ng/ml) and was independent of preimplantation genetic testing for aneuploidy (PGT-A). Conclusion: Intramuscular P4 effectively increased serum P4 levels resulting in pregnancy and neonatal outcomes comparable to those in patients with P4 levels ≥10 ng/ml. This approach provides a safe, effective intervention to improve FET outcomes, supporting the routine inclusion of serum P4 testing and intramuscular P4 rescue in standard FET protocols.
Fertility and SterilityAitken et al.Original Research
The past half century has witnessed a dramatic decline in human fertility as reflected in the total fertility rate. This decline in total fertility rate is thought to have been triggered by an increase in resources and knowledge that precipitated a significant decline in infant mortality. This, in turn, led to a reduction in the desire of couples to have large families, supported in recent times by a series of factors including a delay in childbearing as women acquired the education and autonomy to enter the paid workforce, the progressive urbanization of advanced societies, and, for many, a seismic shift in life's purpose away from procreation and toward self-fulfillment. Notwithstanding the power of such short-acting socioeconomic drivers, they are all potentially reversible given appropriate revisions in governmental policies and societal aspirations. However, we argue that if human societies experience subreplacement levels of fertility for a prolonged period, then there is a danger that our fundamental fecundity (ability to reproduce) will become compromised. A lack of evolutionary selection pressure on fertility, the excessive use of assisted reproductive technology, and the pervasive presence of environmental pollutants in the environment, are all relevant in this context. Addressing the causes of human fertility decline is critical if we are to manage our population rather than become its hapless victim.
Reproductive Biology and EndocrinologyTorkel et al.Qualitative Study
BACKGROUND: While there is a recognised role of lifestyle (diet and physical activity) in management of infertility, there is limited research exploring the perspectives of people with infertility in relation to lifestyle management. The aim of this study was to understand the barriers and enablers affecting uptake of lifestyle intervention in people with infertility who were using or seeking fertility treatment. METHODS: A qualitative descriptive study was performed. Online interviews were conducted with people with infertility who were using or seeking fertility treatment. Interviews explored barriers and enablers to a healthy lifestyle while attempting conception. Interview questions were informed by the Capability, Opportunity, Motivation and Behaviour (COM-B) model and theoretical domains framework (TDF). Interview transcripts were analysed using template analysis. Themes were mapped to the COM-B and TDF, and suggested interventions were developed using the behaviour change wheel method. RESULTS: Nine women and two men completed the interviews. The median age was 38 years (interquartile range 33 to 42 years). Barriers and enablers related to capability (e.g. managing whole-body health and disease), opportunity (e.g. unmet needs from the healthcare system) and motivation (e.g. interplay between lifestyle and emotional state). Suggested intervention components included delivering inclusive programs which accommodate individual needs and providing engaging information which debunks myths and explains the mechanism by which lifestyle promotes fertility. CONCLUSIONS: Our study provides novel and rich insights into the unique needs of people with infertility, and has identified several interacting factors which influence their lifestyle behaviours. Our findings highlight that changes at the organisational and policy level are essential to overcome major barriers to lifestyle management by improving access to trustworthy resources with actionable advice, and by improving service provision to deliver multidisciplinary patient-centred care. Future studies should use these findings to co-design interventions and resources to support lifestyle management of infertility. TRIAL REGISTRATION: Not applicable.
Frontiers in EndocrinologyYe et al.Retrospective Study
Background: fertilization (IVF) or intracytoplasmic sperm injection (ICSI) cycles. Methods: A retrospective cohort study screened 943 patients who underwent IVF/ICSI treatment between February and June 2020 in Shanghai, China, and 828 patients were finally included in the analyses. The body weight, height, waist circumference and hip circumference were measured before ovarian stimulation, and their IVF/ICSI outcomes were followed up. The cut-off point of WHR was determined by the area under the receiver operating characteristic (ROC) curve. Live birth rate from the first embryo transfer cycle was the primary outcome. The secondary outcomes included cumulative live birth, miscarriage rate and birthweight. Results: Women with relatively high WHR (≥0.783) showed lower live birth rate (adjusted odds ratio (aOR): 0.657, 95%CI: 0.466-0.926), lower cumulative live birth rate (aOR: 0.580, 95%CI: 0.413-0.814), and higher miscarriage rate (aOR=2.865, 95%CI: 1.300-6.316) as compared with those with low WHR (<0.783), independently of BMI. Joint WHR and BMI analyses showed that, compared with the reference group (those with low WHR and normal weight), those with high WHR and normal BMI had lower live birth rate (aOR=0.653, 95%CI: 0.447-0.954) and cumulative live birth rate (aOR=0.600, 95%CI: 0.413-0.872), and higher miscarriage rate (aOR=2.865, 95%CI: 1.229-6.676), Whereas the patients with both high WHR and high BMI only showed a significant lower cumulative live birth rate (aOR=0.612, 95%CI: 0.404-0.926). Moreover, there was no significant association between BMI and pregnancy outcomes, or between maternal WHR and birth weights. Conclusions: Our results demonstrated that higher WHR was associated with lower fecundability in women undergoing IVF/ICSI cycles, independently of BMI. Interestingly, the adverse effects of central obesity were more evident in patients with lower BMI. Thus WHR appears to be a better predictor of female fertility treatment outcomes as compared with BMI.
Molecular Human ReproductionZhou et al.Original Research
This study aimed to investigate the benefits of melatonin supplementation during the blastocyst vitrification and thawing process and explore underlying mechanisms to prevent apoptotic events. We evaluated blastocysts in three groups: fresh blastocysts (Control), non-melatonin-treated vitrification (VT), and melatonin-treated vitrification (MVT). We compared their developmental potential and oxidative stress levels to analyse effects of optimized melatonin supplementation. Additionally, transcriptome analysis in blastocysts by Smart-seq2 was performed to investigate the underlying transcriptional mechanism. Antioxidant enzyme and mitochondrial function protein expression were investigated by immunofluorescence staining. Our results showed that supplementation of melatonin to the vitrification and warming solution significantly reduced the apoptotic cell proportion (P < 0.001) while increasing the numbers of inner cell mass (P < 0.001), trophectoderm (P < 0.001), and total cell counts (P < 0.001). Melatonin protected against oxidative stress and restored mitochondrial dysfunction in blastocysts, as evident from increased mitochondrial activity (P < 0.05) and reduced levels of Ca2+ (P < 0.05) and reactive oxygen species (P < 0.05). Importantly, melatonin alleviated cryodamage and preserved blastocyst ultrastructure, and rebalanced altered gene expression induced by the vitrification and warming. These results suggest that adding 10-10 M melatonin to vitrification and warming solutions protects mouse blastocysts against the detrimental effects of oxidative stress and enhances the efficiency of cryopreservation.
Human Reproduction OpenChoi et al.Cohort Study
The Medical Journal of AustraliaCostello et al.Original Research
Introduction The 2024 Australian evidence‐based guideline for unexplained infertility provides clinicians with evidence‐based recommendations for the optimal diagnostic workup for infertile couples to establish the diagnosis of unexplained infertility and optimal therapeutic approach to treat couples diagnosed with unexplained infertility in the Australian health care setting. The guideline recommendations were adapted for the Australian context from the rigorous, comprehensive European Society of Human Reproduction and Embryology (ESHRE) 2023 Evidence‐based guideline: unexplained infertility , using the ADAPTE process and have been approved by the Australian National Health and Medical Research Council. Main recommendations The guideline includes 40 evidence‐based recommendations, 21 practice points and three research recommendations addressing: definition — defining infertility and frequency of intercourse, infertility and age, female and male factor infertility; diagnosis — ovulation, ovarian reserve, tubal factor, uterine factor, laparoscopy, cervical/vaginal factor, male factor, additional testing for systemic conditions; and treatment — expectant management, active treatment, mechanical‐surgical procedures, alternative therapeutic approaches, quality of life. Changes in assessment and management resulting from the guideline This guideline refines the definition of unexplained infertility and addresses basic diagnostic procedures for infertility assessment not considered in previous guidelines on unexplained infertility. For therapeutic approaches, consideration of evidence quality, efficacy, safety and, in the Australian setting, feasibility, acceptability, cost, implementation and ultimately recommendation strength were integrated across multidisciplinary expertise and consumer perspectives in adapting recommendations to the Australian context by using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework, which had not been used in past guidelines on unexplained infertility to formulate recommendations. The Australian process also included an established data integrity check to ensure evidence could be trusted to guide practice. Practice points were added and expanded to consider the Australian setting. No evidence‐based recommendations were underpinned by high quality evidence, with most having low or very low quality evidence. In this context, research recommendations were made including those for the Australian context. The full guideline and technical report are publicly available online and can be accessed at https://www.monash.edu/medicine/mchri/infertility and are supported by extensive translation resources, including the free patient ASKFertility mobile application ( https://www.askfertility.org/ ).
The Medical Journal of AustraliaTeede et al.Original Research
The Australian-led 2023 International evidence-based guideline for the assessment and management of polycystic ovary syndrome was based on best available evidence, clinical expertise and consumer preference. It followed best practice, involved extensive evidence synthesis and applied relevant frameworks across evidence quality, feasibility, acceptability, cost and implementation. Thirty-nine societies and organisations covering 71 countries were engaged. The evidence in the assessment and management of polycystic ovary syndrome (PCOS) has generally improved in the past five years, but remains of low to moderate quality. The technical evidence report, 52 systematic reviews and analyses (approximately 6000 pages) underpin 77 evidence-based and 54 consensus recommendations, with 123 practice points.
EClinicalMedicineMousa et al.Guideline
Background: Clinical guidelines rely on sound evidence to underpin recommendations for patient care. Compromised research integrity can erode public trust and the credibility of the scientific enterprise, with potential harm to patients. Despite increased recognition of integrity concerns in scientific literature, there are no processes or guidance for incorporating integrity assessments into evidence-based guideline development or evidence synthesis more broadly. Methods: ence synthesis (RIGID) framework. Co-developed with international input from 80 multidisciplinary experts, and consumers, the RIGID framework and accompanying checklist provide an innovative and transparent six-step approach to assess the integrity of studies during the synthesis of evidence, including in the development of clinical guidelines. Central to the framework is an integrity committee, responsible for objective assessments and allocations, with constructive author engagement. Findings: The six key steps of the RIGID framework are described, as follows: (1) Review: standard systematic review processes are followed, in line with approved evidence synthesis methodologies; (2) Exclude: studies which have been retracted are excluded, and those with expressions of concern are flagged for further evaluation; (3) Assess: remaining studies are assessed for integrity using an appropriate tool and allocated an initial integrity risk rating of low, moderate or high risk for integrity concerns; (4) Discuss: integrity assessment results are discussed among integrity committee members with votes to determine final integrity risk rating allocations for each study; (5) Establish contact: low risk studies are included without author contact, whereas authors of studies ranked as moderate or high risk are contacted for clarification; (6) Reassess: studies are reassessed for inclusion using the RIGID author response algorithm (reclassified as 'included' where authors have provided a satisfactory response, 'awaiting classification' where authors have engaged but time is needed to address concerns, or 'not included' where authors have not responded to contact attempts). An illustrative case study is presented, where these six steps of the RIGID framework were successfully implemented in an influential international guideline endorsed by 39 societies across six continents. Following implementation of the framework, 45 of the 101 originally identified studies (45%) were not included in the guideline. Interpretation: Based on the latest literature and international expertise, the RIGID framework represents an important advancement in best practice standards for guideline development and evidence synthesis. Using this resource, guideline developers, policy-makers, clinicians and scientists are better positioned to navigate the currently precarious research landscape to ensure evidence synthesis and subsequent clinical recommendations prioritize patient care and preserve the sanctity of scientific endeavors. Funding: This study received no specific funding. The guideline in which it was piloted was supported by the Australian National Health and Medical Research Council (NHMRC) for guideline development through the Centre of Research Excellence (CRE) in Women's Health in Reproductive Life (CRE-WHiRL) (APP1171592) and the CRE in Polycystic Ovary Syndrome (CRE-PCOS) (APP1078444) led by Monash University, Australia, and partner societies: the American Society for Reproductive Medicine (ASRM), the US Endocrine Society (ENDO), the European Society of Endocrinology (ESE) and the European Society of Human Reproduction and Embryology (ESHRE).
Human ReproductionHo et al.RCT
Study question Are live birth rates after natural (NC), modified natural (mNC) endometrial preparation superior to artificial cycle (AC) strategies for ovulatory women undergoing frozen embryo transfer? Summary answer Live birth rates were comparable between NC, mNC, and AC. However, NC and mNC resulted in a significantly higher cycle cancellation rate. What is known already The number of frozen embryo transfer (FET) cycles has increased dramatically. In ovulatory women undergoing FET, three common strategies can be used for endometrial preparation: NC, mNC (NC + human chorionic gonadotropin trigger), and AC protocols. Previous studies comparing the effectiveness of these strategies had several drawbacks, including small sample size, lack of consistency between studies in the assessment and reporting of outcomes, and the retrospective origin, which introduced potential biases. Therefore, there is a lack of consensus on the optimal endometrial preparation protocol for FET. Study design, size, duration This single-center, open-label, randomized controlled trial was conducted at IVFMD, My Duc Hospital in Ho Chi Minh City, Vietnam. From March 2021 to March 2022, a total number of 1,428 participants were randomized (476 per group). The primary outcome of the study was live birth after one FET. Secondary outcomes were fertility outcomes, early pregnancy complications, obstetrical outcomes, perinatal and neonatal complications, and endometrial preparation cycle cancellation rates. Participants/materials, setting, methods Eligible participants were ovulatory women aged 18–45 with FET treatment, underwent no more than three IVF/intracytoplasmic sperm injection-FET cycles, had no more than two day-3 or one blastocyst transferred. Women with menopause/anovulation, contraindications for hormonal administration, uterine abnormalities who underwent in-vitro maturation, pre-implantation genetic testing, oocyte donation cycles were excluded. The FET strategies included FET after the first endometrial preparation cycles with AC, mNC, or NC, as per randomization, and the second with AC. Main results and the role of chance A total of 4,779 participants were screened, of whom 1,428 eligible individuals (476 per group) were randomized after written informed consent. The live birth rate after one FET was 36.6% (174/476) in the natural cycle strategy group, 33.4% (159/476) in the modified natural cycle strategy group, and 34.0% (162/476) in the artificial cycle strategy group (relative risk [95% confidence interval] for natural versus artificial cycle strategy: 1.07 [0.87–1.33] and for modified natural versus artificial cycle strategy: 0.98 [0.79–1.22]). Maternal and neonatal outcomes were comparable between groups, in particular,hypertensive disorders in pregnancy. For both natural and modified cycle groups, 20.08% (99/476) of the first FET cycles were canceled before subsequent successful ET versus none in the artificial cycle group. Limitations, reasons for caution Due to the nature of the intervention, blinding was not possible. The study was conducted in ovulatory women in a single center in Vietnam, which may limit the generalisability of the findings. Wider implications of the findings Live birth rates and obstetric/neonatal outcomes after the natural cycle, modified natural cycle, or artificial cycle strategies for ovulatory women undergoing FET are comparable, with higher cancellation rates in both the natural cycle and the modified natural cycle groups. Trial registration number NCT04804020
Human ReproductionDuong et al.Clinical Trial
Study question What is the effectiveness of swim-up (SU) and density gradients (DG) for sperm preparation in infertile couples undergoing intrauterine insemination (IUI)? Summary answer In couples undergoing IUI, there is no significant difference in the treatment outcomes between SU and DG. What is known already Swim-up (SU) and density gradients (DG) are the most two commonly used techniques for sperm preparation in intrauterine insemination (IUI). The latest Cochrane review concluded that there is uncertainty about the effectiveness of SU versus DG and no studies reported on live birth. Study design, size, duration This open-label, multi-centre randomised clinical trial was conducted on 912 infertile couples at a tertiary IVF center, Ho Chi Minh City, Vietnam from August 2020 to June 2023. Couples were randomly asigned to two groups, SU and DG using computerized randomisation on the day of IUI with variable block size of 2, 4 or 6. Primary outcome was live birth rate. Participants/materials, setting, methods Infertile couples were eligible if aged ≥18, indicated for IUI with ≤2 IUI prior attempts and husbands’ sperm concentration ≥5x106/ml, progressive motility (PR) ≥32% and total PR sperm count >5x106 before sperm preparation (WHO 2010 criteria). Couples using frozen semen, or high viscosity semen were not eligible. Women had ovulation induction using hMG. Sperm preparation was performed within one hour after ejaculation. IUI was performed once at 36 to 40 hours after hCG trigger. Main results and the role of chance Between August 2020 and June 2023, 912 couples were randomly assigned to SU (n = 456) or DG (n = 456). Baseline characteristics were comparable between the two groups (mean female age of 31.3 ± 0.4 years; total sperm count: 86.2 [52.9;137.6] million; sperm motility: 44.8 ± 8.2%). Live birth occurred in 55 (12.1%) couples in the SU group and 71 (15.7%) couples in the DG group (RR 0.77; 95% CI 0.56-1.07). Ongoing pregnancy and multiple pregnancy were also comparable between the two groups. There were no statistically significant differences between the SU and DG groups with respect to the occurrence of pregnancy complications, obstetric and perinatal complications, preterm delivery, birth weight and neonatal complications. Pre-planned subgroup analysis showed that the live birth rate was not materially affected by the IUI indications, total motile sperm after preparation (<1, ≥1 and <5, ≥5 and <10 and ≥10 million). Limitations, reasons for caution The main limitation of the study was its open-label design, due to the nature of the interventions. Wider implications of the findings Our study suggests that in couples undergoing IUI with progressive motility (PR) ≥32% and total PR sperm count >5x106 before sperm preparation, SU or DG can both be used for sperm preparation, with a preference for density gradients. Trial registration number NCT04477356
Human ReproductionSandhu et al.RCT
Does a purpose-designed Decision Aid for women considering elective egg freezing (EEF) impact decisional conflict and other decision-related outcomes?